Open AccessLIGHT CHAIN MULTIPLE MYELOMA: A CASE REPORT
Author(s) -
Shamsudeen Moideen,
- MAHESHWARI,
Raghuveer Prabhu
Publication year - 2020
Publication title -
international research journal of pharmacy
Language(s) - English
Resource type - Journals
ISSN - 2230-8407
DOI - 10.7897/2230-8407.111081
Subject(s) - multiple myeloma , immunoglobulin light chain , medicine , bence jones protein , bortezomib , plasmacytoma , kappa , histopathology , myeloma protein , pathology , antibody , gastroenterology , immunology , linguistics , philosophy
Light chain multiple myeloma (LCMM) initiates approximately 15 percentage of patients with multiple myeloma (MM). It has a lower prognosis when compared with the variant immunoglobulin (Ig) G or IgA. We report a rare case on Light chain multiple myeloma in 49-year-old male patient who presented with acute kidney injury, hypercalcemia. histopathology examination was found to be plasmacytoma, kappa restricted; and free kappa lamda chain in urine and serum was found to be greater. Bone pain and renal dysfunction were the most common prevalent initial signs and symptoms while extramedullary disease (EMD) was later acquired during disease. Bortezomib demonstrated superior efficacy over nonbortezomib in LCMM patients.